Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer.
DISEASE MARKERS 2022;
2022:8426384. [PMID:
35996715 PMCID:
PMC9392629 DOI:
10.1155/2022/8426384]
[Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Accepted: 05/13/2022] [Indexed: 12/11/2022]
Abstract
Objective
To explore the expression and clinical significance of HER2 and DNMT1 in non-small-cell lung cancer.
Methods
The patients with non-small-cell lung cancer treated in the First Affiliated Hospital of Jiamusi University between 2018 and 2020 were enrolled in this study. The serum DNMT1 concentration and the expression of HER2 protein in lung cancer and adjacent tissues of the two groups were analyzed.
Results
The DNMT1 protein concentration was significantly correlated with gender, age, and smoking history of patients. HER2-positive expression was significantly related to tumor type, tumor size, tumor differentiation degree, and lymph node metastasis. However, HER2 levels were not related to the gender and smoking history of patients.
Conclusion
High expression of DNMT1 protein in serum may increase the risk of non-small-cell lung cancer and may play an important role in the early development of lung cancer. HER2-positive expression may promote the development of advanced and metastatic non-small-cell lung cancer.
Collapse